CDKN2A

Across TCGA pan-cancer cohorts, CDKN2A Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CDKN2A data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CDKN2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDKN2A expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

KIRP, PAAD, and LIHC are the cancer types where CDKN2A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.111	0.934	<.001	42	view →
PAAD	DFS	Median	All	0.075	0.473	<.001	30	view →
LIHC	DFS	Median	III,IV	0.046	0.361	<.001	12	view →
SKCM	DFS	Median	IV	0.052	0.475	.038	6	view →
UCEC	DFS	Median	All	0.964	0.632	.025	6	view →
CHOL	OS	Median	All	0.154	0.793	.004	3	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →
HNSC	OS	Median	All	0.572	0.676	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CDKN2A–KIRP (OS)

Open the KIRP breakdown →